Navigation Links
Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
Date:5/10/2011

ROCKVILLE, Md., May 10, 2011 /PRNewswire/ --Neuralstem, Inc. (NYSEAmex: CUR)  reported its financial results for the three months period ended March 31, 2011 and provided a business and clinical update.  

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"The Company reached several major milestones in the first Quarter of 2011.  Interim data from our Phase I trial for ALS was presented at the American Academy of Neurology Annual Meeting in April, where the principal investigator of the trial, Dr. Eva Feldman, reported the ground-breaking work was both feasible and safe," said Neuralstem's Chairman and Chief Scientific Officer Karl Johe, PhD. "We completed all of the transplantations for the first 12-patient cohort in our ALS trial in mid-April. Also, in February, the U.S. FDA Office of Orphan Products Development granted the Company orphan drug designation for the cell therapy treatment of ALS with its human spinal cord-derived neural stem cells (NSI-566RSC)."

"Further, after receiving approval from the FDA late in 2010 for our first small molecule drug  trial, NSI-189 for major depression, we began dosing in our phase 1a patients in February," said Dr. Johe. "Looking forward, we expect the FDA to approve the second part of the Phase I ALS trial this summer. The next group of patients will receive injections in the upper spinal cord area, where we believe that the injections can ultimately aid in the preservation of respiratory capacity for ALS patients. Additionally, we expect the NSI-189 major depression trial to proceed to Phase Ib with escalating dosing of depressed patients this summer.  The small molecule program has been strengthened by the addition of Maurizio Fava, MD, Director of the Massachusetts General Hospital Department of Psychiatry Clinical Trials Network and Institute, who is now consulting on the trial des
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
2. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
3. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
4. Neuralstem Completes $5.25 Million Financing
5. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
8. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
9. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
10. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
11. Neuralstem Reports Second Quarter Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
(Date:1/14/2014)... City, Panama (PRWEB) January 14, 2014 ... has received the county’s first clinical trial approval ... umbilical cord-derived mesenchymal stem cells (MSC) from the ... Review Board (IRB). , Rheumatoid Arthritis (RA) is ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... OAB Drug in China, PLYMOUTH MEETING, Pa., ... BJGP ) ("BMP Sunstone" or the "Company") today,announced ... was officially accepted by China,s State Food & ... requirement prior to,pursuing a clinical trial and, ultimately, ...
... Programs Supported by a Grant from Otsuka ... America Pharmaceutical, Inc., ROCKVILLE, ... nonprofit organizations and one individual,as the recipients of the fifth annual ... the 2008 APF Annual Benefit in,Washington, D.C. Each organization or individual ...
... 6 Biomatrica, the leader in room,temperature biological sample ... as Vice President of Sales and Marketing.,Biomatrica,s interim Vice ... integral part of the company and will continue to ... Ms. Dowling brings fourteen years of sales and marketing ...
Cached Biology Technology:BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 2BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 2American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 4American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 5Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2
(Date:4/23/2014)... pair of bioethics experts have added "playwright" to their ... in grappling with an onslaught of ethical issues as ... the human genome was first sequenced. , Until ... W. Bush have been performed for, and by, their ... conferences, meetings and in classrooms. With Oxford University ...
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
(Date:4/23/2014)... source of a unique rhythmic sound, recorded for decades ... the Antarctic minke whale ( Balaenoptera bonaerensis ). First ... who thought it sounded like a duck, the bio-duck ... Southern Ocean, but its source has remained a mystery, ... of researchers deployed acoustic tags on two Antarctic minke ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... from the University of Copenhagen and the Technical University ... the US found that the bacterium Pseudomonas aeruginosa ... white blood cells preventing the bacteria being eliminated ... aeruginosa is responsible for many hospital-acquired infections and ...
... 2009 / b3c newswire /- PlatformQ , ... healthcare, education and energy markets, and LabRoots , a ... that Mark Vachon, the President and CEO for GE Healthcares ... Thursday November 19th at 2:00 PM. GE Healthcare ...
... Rockville, Md. (Oct. 30, 2009) A collaborative research team ... Australian Animal Health Laboratory and National Cancer Institute, a component ... forward in the development of an effective therapy against two ... results of this finding appear Oct. 30, 2009, in the ...
Cached Biology News:Bacteria 'launch a shield' to resist attack 2GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live 2USU scientists report major advance in human antibody therapy against deadly Nipah virus 2USU scientists report major advance in human antibody therapy against deadly Nipah virus 3
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: